Argenx sets ALKIVIA results date as Argenx stock costs EUR 774.70

Published on 10/21/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ALKIVIA showed a 15.4-point treatment advantage at 52 weeks. Argenx stock costs EUR 774.70 on October 21, 2026 versus EUR 780.20.

Upcoming catalysts and recent results

ALKIVIA showed a 15.4-point treatment advantage on October 19, 2026.
Second-quarter revenue reached USD 1.54 billion versus USD 1.45 billion expected.
Argenx stock traded at EUR 774.70 at 10:12 a.m. CEST at Lang & Schwarz on October 21, 2026.

Redaktionelles Börsenfoto: Leuchtende Handelsdisplays mit grünen Aufwärtskurven im Biotech-Sektor, verschwommener Handelssaal im Hintergrund, Atmosphäre des Finanzjournalismus — Argenx NL0010832176 leuchtende Handelsbildschirme an der Euronext zeigen steigende grüne Kurven für Biotech-Aktien, Illustration mit AI erstellt.

Argenx (ISIN NL0010832176) is preparing to present Phase 3 ALKIVIA results after the autoimmune myositis study delivered a 15.4-point treatment advantage at 52 weeks, according to Ideal Investisseur on October 20, 2026. The data are scheduled for a late-breaking presentation at the ACR Convergence Congress on November 11, 2026.

ALKIVIA adds a pipeline catalyst

The ALKIVIA result gives Argenx a positive clinical milestone while the company prepares its next financial update. The study tested efgartigimod in autoimmune myositis, extending the development case for the VYVGART franchise beyond its established indications.

That catalyst sits beside a more complicated research picture. On October 8, 2026, Argenx said it would discontinue the Phase 3 UNITY study in Sjögren's disease after an interim futility recommendation, while its FB102 Phase 2 celiac disease study met its primary endpoint with a p-value of 0.0176 in 126 patients, according to StockTitan.

What does the next report test?

Argenx's second-quarter revenue reached USD 1.54 billion, compared with USD 1.45 billion expected, while diluted earnings per share came to USD 7.32, versus USD 5.86 consensus, according to MarketBeat. Those figures make commercial execution the key test for the third-quarter update, especially as analysts track demand for VYVGART and its pre-filled syringe format.

The next reporting event is scheduled for October 22, 2026, when Argenx will discuss third-quarter financial results and provide a business update during a conference call at 2:30 p.m. CET, according to the company announcement carried by Yahoo Finance. The date gives investors a near-term checkpoint for the commercial outlook.

Analyst targets reflect two risks

RBC Capital lowered its target from USD 1,100 to USD 1,025 while keeping an Outperform rating on October 20, 2026, according to Investing.com. The cut shows how the discontinued UNITY study remains a counterweight to positive pipeline data.

Stock price and next catalyst

Argenx stock was trading at EUR 774.70 at Lang & Schwarz on October 21, 2026 at 10:12 a.m. CEST. On Euronext Brussels, it had closed at EUR 780.20 on October 20, 2026.

The further course of trading is shown by the continuously updated real-time quote of Argenx stock.